Ghost Shave only knows Minoxidil?

*Read only for medical professionals Reference Is baricitinib effective in treating alopecia areata? NEJM gave a phase III RCT to prove that alopecia areata is an autoimmune disease characterized by rapid loss of hair, eyebrows and eyelashes.
At present, there is still no effective treatment
.

Baricitinib, an oral selective and reversible Janus kinase 1 and 2 inhibitor, may interrupt molecular signaling associated with alopecia areata for therapeutic effect
.

The results of two phase III randomized controlled trials (RCTs) published in the New England Journal of Medicine revealed the efficacy and safety of baricitinib in the treatment of alopecia areata
.

This study completed two randomized, placebo-controlled Phase 3 trials: BRAVE-AA1 (n=654) and BRAVE-AA2 (n=546) in adult patients with severe alopecia areata with both Severity Severity Alopecia (SALT) scores ≥50 points (ranging from 0 [no hair loss] to 100 [full scalp hair loss])
.

They were randomly assigned in a 3:2:2 ratio to baricitinib 4 mg once daily, baricitinib 2 mg and placebo
.

The primary outcome was a SALT score ≤20 at week 36
.

The main results were as follows: (1) In BRAVE-AA1, the percentage of patients with SALT score ≤20 at week 36 were: 38.
8% for baricitinib 4 mg, 22.
8% for baricitinib 2 mg, and 6.
2% for placebo; BRAVE- In AA2, they were 35.
9%, 19.
4% and 3.
3%, respectively
.

(2) In BRAVE-AA1, the difference between baricitinib 4 mg and placebo group was 32.
6% (95% CI, 25.
6-39.
5), and the difference between baricitinib 2 mg and placebo group was 16.
6% (95% CI, 9.
5-23.
8) ) (both P<0.
001 versus placebo); the corresponding values ​​in BRAVE-AA2 were 32.
6% (95%CI, 25.
6-39.
6), 16.
1% (95%CI, 9.
1-23.
2) (compared to placebo) , P all <0.
001)
.

(3) The secondary outcome of baricitinib 4 mg (not 2 mg) generally favored baricitinib over placebo
.

(4) Acne, increased creatine kinase levels, and increased low-density and high-density lipoprotein cholesterol levels were more common in the baricitinib group compared with placebo
.

The above two phase III trials of alopecia areata showed that oral baricitinib for 36 weeks was more effective in hair regrowth than placebo
.

Longer observational data are still needed to assess the efficacy and safety of baricitinib in the treatment of alopecia areata
.

Want to see more of the previous issues of "Top Issue Highlights"? Come to the "Clinical Decision Assistant" service number to have a look! 1.
Click the business card below to follow the official account of "Clinical Decision Assistant" 2.
Find the "Top Journal Highlights" in the menu bar 3.
View the latest journals in various disciplines 4.
You can also click "Subscription Settings" 5.
Subscribe to the disciplines you care about The subject is pushed every day, and a new top issue is read every day! Such a useful tool, let's use it! References: [1] King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM , Sinclair R;BRAVE-AA Investigators.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
N Engl J Med.
2022 Mar 26.
doi:10.
1056/NEJMoa2110343.
Epub ahead of print.
PMID:35334197.